Community

Andrew Bulpin, Ph.D.

Head of Process Solutions Strategic, Marketing and Innovation, MilliporeSigma

Andrew Bulpin is Executive Vice President of Process Solutions for the life science business of Merck KGaA, Darmstadt, Germany, and is based in Bedford, MA. He joined the organization in 2006 as Vice President of Upstream Processing and later assumed leadership of the Services and Solutions business. He has also served as Global Head of Sales for Pharmaceutical Chemical Solutions.

Contributions

Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?

Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?

Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?

Q: What advances in manufacturing technology are most enabling the scale-up and commercialization of next-generation therapies?

Q: What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?

Q: If You Could Have One Piece of Biologic Manufacturing Equipment Improved, What Would It Be and Why?

Q: How is Growth in the Biosimilars Market Impacting the Development of New Biologics Manufacturing Equipment Technologies?

Q: Has Downstream Processing Technology Caught up with the Significantly Higher Titers Coming Out of the Current Upstream Process? If No, What Issues Remain?

Q: What is the Most Significant Recent Advancement in Downstream Bioprocessing Technology? Why is it so Important?